File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: "Cytomegalovirus disease" in renal allograft recipients: Is human herpesvirus 7 a Co-factor for disease progression?

Title"Cytomegalovirus disease" in renal allograft recipients: Is human herpesvirus 7 a Co-factor for disease progression?
Authors
KeywordsHuman herpesvirus 6
PCR
Renal transplantation
Serology
Viral co-factor
Issue Date1996
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763
Citation
Journal Of Medical Virology, 1996, v. 48 n. 4, p. 295-301 How to Cite?
AbstractFifty-six renal allograft recipients were studied prospectively for 3 months or longer after transplant. The polymerase chain reaction (PCR) was used to screen peripheral blood leucocyte (PBL) specimens for CMV, human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7) DNA (DNAemia) in 67 healthy controls and in serial (fortnightly) PBL specimens from the 56 allograft recipients. None of the healthy controls had detectable CMV DNAemia, although HHV6 and HHV7 DNAemia was found in 7% and 9% of individuals respectively. In contrast, DNAemia due to CMV, HHV6 and HHV7 was found in 50%, 36% and 39% of patients respectively, at some time during the post-transplant period. Of the 28 patients who had CMV DNAemia, eight developed "CMV disease." The risk of progression to "CMV disease" was increased in patients with concurrent DNAemia to all three viruses (relative risk 3.7; 95% Cl 1.3-10.5). The relative risk of "CMV disease" for patients with concurrent CMV and HHV7 was also increased (RR = 3.5; 95% Cl = 1.1-11.6), while the association between CMV and HHV6 was inconclusive (RR = 2.1; 95% Cl = 0.7-6.6). The first 26 patients recruited to the study also had serial serum samples tested for antibody responses to the three viruses. "CMV disease" was associated with rising antibody titres to HHV7 (Fisher's exact test, P = 0.02), and weakly so with HHV6 (P = 0.07). It is concluded that in patients with CMV DNAemia, concurrent infection/reactivation of HHV7 (and possibly HHV6) is associated with an increased risk of progression to "CMV disease. " © 1996 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/179757
ISSN
2021 Impact Factor: 20.693
2020 SCImago Journal Rankings: 0.782
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorOsman, HKEen_US
dc.contributor.authorPeiris, JSMen_US
dc.contributor.authorTaylor, CEen_US
dc.contributor.authorWarwicker, Pen_US
dc.contributor.authorJarrett, RFen_US
dc.contributor.authorMadeley, CRen_US
dc.date.accessioned2012-12-19T10:04:22Z-
dc.date.available2012-12-19T10:04:22Z-
dc.date.issued1996en_US
dc.identifier.citationJournal Of Medical Virology, 1996, v. 48 n. 4, p. 295-301en_US
dc.identifier.issn0146-6615en_US
dc.identifier.urihttp://hdl.handle.net/10722/179757-
dc.description.abstractFifty-six renal allograft recipients were studied prospectively for 3 months or longer after transplant. The polymerase chain reaction (PCR) was used to screen peripheral blood leucocyte (PBL) specimens for CMV, human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7) DNA (DNAemia) in 67 healthy controls and in serial (fortnightly) PBL specimens from the 56 allograft recipients. None of the healthy controls had detectable CMV DNAemia, although HHV6 and HHV7 DNAemia was found in 7% and 9% of individuals respectively. In contrast, DNAemia due to CMV, HHV6 and HHV7 was found in 50%, 36% and 39% of patients respectively, at some time during the post-transplant period. Of the 28 patients who had CMV DNAemia, eight developed "CMV disease." The risk of progression to "CMV disease" was increased in patients with concurrent DNAemia to all three viruses (relative risk 3.7; 95% Cl 1.3-10.5). The relative risk of "CMV disease" for patients with concurrent CMV and HHV7 was also increased (RR = 3.5; 95% Cl = 1.1-11.6), while the association between CMV and HHV6 was inconclusive (RR = 2.1; 95% Cl = 0.7-6.6). The first 26 patients recruited to the study also had serial serum samples tested for antibody responses to the three viruses. "CMV disease" was associated with rising antibody titres to HHV7 (Fisher's exact test, P = 0.02), and weakly so with HHV6 (P = 0.07). It is concluded that in patients with CMV DNAemia, concurrent infection/reactivation of HHV7 (and possibly HHV6) is associated with an increased risk of progression to "CMV disease. " © 1996 Wiley-Liss, Inc.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/32763en_US
dc.relation.ispartofJournal of Medical Virologyen_US
dc.subjectHuman herpesvirus 6-
dc.subjectPCR-
dc.subjectRenal transplantation-
dc.subjectSerology-
dc.subjectViral co-factor-
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntibodies, Viral - Blooden_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshCytomegalovirus - Genetics - Immunology - Isolation & Purificationen_US
dc.subject.meshCytomegalovirus Infections - Complications - Immunology - Virologyen_US
dc.subject.meshDna, Viral - Analysisen_US
dc.subject.meshDisease Progressionen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHerpesviridae Infections - Complications - Immunology - Virologyen_US
dc.subject.meshHerpesvirus 6, Human - Genetics - Immunology - Isolation & Purificationen_US
dc.subject.meshHerpesvirus 7, Human - Genetics - Immunology - Isolation & Purificationen_US
dc.subject.meshHumansen_US
dc.subject.meshKidney Transplantation - Adverse Effectsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshTransplantation, Homologousen_US
dc.title"Cytomegalovirus disease" in renal allograft recipients: Is human herpesvirus 7 a Co-factor for disease progression?en_US
dc.typeArticleen_US
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hken_US
dc.identifier.authorityPeiris, JSM=rp00410en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/(SICI)1096-9071(199604)48:4<295::AID-JMV1>3.0.CO;2-2-
dc.identifier.pmid8699160-
dc.identifier.scopuseid_2-s2.0-0029866064en_US
dc.identifier.hkuros14623-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0029866064&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume48en_US
dc.identifier.issue4en_US
dc.identifier.spage295en_US
dc.identifier.epage301en_US
dc.identifier.isiWOS:A1996UD03500001-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridOsman, HKE=7005733119en_US
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_US
dc.identifier.scopusauthoridTaylor, CE=7404822545en_US
dc.identifier.scopusauthoridWarwicker, P=6602814529en_US
dc.identifier.scopusauthoridJarrett, RF=7101848439en_US
dc.identifier.scopusauthoridMadeley, CR=7006274504en_US
dc.identifier.issnl0146-6615-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats